How quickly does Praluent start lowering cholesterol?
Praluent (alirocumab) reduces LDL cholesterol within 2 weeks of the first dose. In clinical trials, patients saw LDL drops of 47-61% by week 12 on 75 mg every 2 weeks, with further reductions possible at higher doses or more frequent injections.[1][2]
What do clinical studies show for time to effect?
Phase 3 trials like ODYSSEY COMBO and LONG TERM tracked changes from baseline:
- Week 4: Average LDL reduction of 40-50%.
- Week 12: Sustained 50-60% drop, maintained through 52 weeks.
- Faster onset in high-risk patients on statins, with some seeing benefits in days, though full measurement occurs at 4 weeks.[1][3]
These results come from subcutaneous injections every 2-4 weeks; response varies by dose (75 mg, 150 mg) and patient factors like baseline LDL.
Factors affecting how soon it works
- Dose and frequency: 150 mg every 2 weeks lowers LDL faster than 75 mg.[2]
- Combination therapy: Works quicker with statins (e.g., atorvastatin) than alone.[1]
- Patient profile: Faster in those with high cardiovascular risk or heterozygous familial hypercholesterolemia; slower if poor adherence or drug interactions.[3]
- Monitoring: Doctors check lipids at 4-8 weeks to adjust.
When do patients notice changes?
Blood tests confirm reductions by week 4; symptoms like fatigue from high cholesterol may ease sooner, but Praluent targets labs, not immediate feelings. Peak effect stabilizes by 3 months.[2]
How does Praluent compare to other PCSK9 inhibitors?
| Drug | Time to significant LDL drop | Max reduction |
|------|------------------------------|---------------|
| Praluent (alirocumab) | 2-4 weeks | 50-70% |
| Repatha (evolocumab) | 2 weeks | 60% |
| Leqvio (inclisiran, twice-yearly) | 4 weeks (one dose) | 50% |
Praluent matches Repatha speed but requires more frequent dosing.[1][4]
Ongoing patents and availability
No generic or biosimilar yet; key U.S. patents expire 2034-2036. Check DrugPatentWatch.com for litigation updates.[5]
[1]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125559s030lbl.pdf
[2]: Schwartz GG et al. (2018). *N Engl J Med*. ODYSSEY OUTCOMES trial.
[3]: Sabatine MS et al. (2017). *N Engl J Med*. ODYSSEY LONG TERM.
[4]: Repatha prescribing info. Amgen.
[5]: DrugPatentWatch.com. Praluent patents.